Evergreen Capital Management LLC Has $9.70 Million Stake in Johnson & Johnson $JNJ

Evergreen Capital Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 10.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 63,507 shares of the company’s stock after purchasing an additional 5,880 shares during the quarter. Evergreen Capital Management LLC’s holdings in Johnson & Johnson were worth $9,701,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of JNJ. Norges Bank purchased a new position in Johnson & Johnson during the 2nd quarter worth $4,877,174,000. Laurel Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 15,040.6% during the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock worth $1,133,512,000 after purchasing an additional 7,371,687 shares during the last quarter. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after purchasing an additional 3,085,180 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after buying an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $401,420,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $211.65 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $212.27. The firm has a 50 day moving average of $196.09 and a 200 day moving average of $177.25. The firm has a market capitalization of $509.93 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 2.36 and a beta of 0.36. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research report on Monday, October 20th. Guggenheim lifted their target price on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday. Citigroup raised their price objective on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Bank of America raised their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $207.55.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.